Eloxx Pharmaceuticals Inc
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bul… Read more
Eloxx Pharmaceuticals Inc (ELOX) - Total Assets
Latest total assets as of September 2023: $6.04 Million USD
Based on the latest financial reports, Eloxx Pharmaceuticals Inc (ELOX) holds total assets worth $6.04 Million USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eloxx Pharmaceuticals Inc - Total Assets Trend (1998–2022)
This chart illustrates how Eloxx Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eloxx Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Eloxx Pharmaceuticals Inc's total assets of $6.04 Million consist of 95.3% current assets and 4.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2022)
This chart illustrates how Eloxx Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eloxx Pharmaceuticals Inc's current assets represent 95.3% of total assets in 2022, an increase from 88.4% in 1998.
- Cash Position: Cash and equivalents constituted 90.9% of total assets in 2022, up from 87.3% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Eloxx Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Eloxx Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Eloxx Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Eloxx Pharmaceuticals Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Eloxx Pharmaceuticals Inc is currently not profitable relative to its asset base.
Eloxx Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.24 | 1.18 | 6.45 |
| Quick Ratio | 0.24 | 1.18 | 6.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-17.84 Million | $ 3.99 Million | $ 42.53 Million |
Eloxx Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Eloxx Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.31 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -53.2% |
| Total Assets | $21.12 Million |
| Market Capitalization | $290.71 USD |
Valuation Analysis
Below Book Valuation: The market values Eloxx Pharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Eloxx Pharmaceuticals Inc's assets decreased by 53.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eloxx Pharmaceuticals Inc (1998–2022)
The table below shows the annual total assets of Eloxx Pharmaceuticals Inc from 1998 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $21.12 Million | -53.20% |
| 2021-12-31 | $45.14 Million | +73.44% |
| 2020-12-31 | $26.03 Million | -55.85% |
| 2019-12-31 | $58.95 Million | +16.23% |
| 2018-12-31 | $50.72 Million | +767.69% |
| 2017-12-31 | $5.85 Million | -36.64% |
| 2016-12-31 | $9.23 Million | -52.80% |
| 2015-12-31 | $19.55 Million | -41.36% |
| 2014-12-31 | $33.33 Million | +369.65% |
| 2013-12-31 | $7.10 Million | +2.05% |
| 2012-12-31 | $6.95 Million | -19.10% |
| 2011-12-31 | $8.60 Million | -38.20% |
| 2010-12-31 | $13.91 Million | +57.75% |
| 2009-12-31 | $8.82 Million | -17.14% |
| 2008-12-31 | $10.64 Million | +220.40% |
| 2007-12-31 | $3.32 Million | -6.04% |
| 2006-12-31 | $3.54 Million | -42.17% |
| 2005-12-31 | $6.11 Million | +17.31% |
| 2004-12-31 | $5.21 Million | +59.56% |
| 2003-12-31 | $3.27 Million | -37.56% |
| 2002-12-31 | $5.23 Million | +1810.59% |
| 2001-12-31 | $273.75K | -84.30% |
| 2000-12-31 | $1.74 Million | +60.76% |
| 1999-12-31 | $1.08 Million | 0.00% |
| 1998-12-31 | $1.08 Million | -- |